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Background: Disease modifying therapy (DMT) efficacy trials make an essential
contribution to the development of evidence-based clinical treatments and practices for
people with multiple sclerosis (MS). Meta-analysis is a critical part of this process and
provides a powerful tool to assess the effects of DMT on MS progression. However,
although there have been several meta-analyses on the effect of DMT on MS disease
progression, they often do not reach the same conclusions.
Objective: Our aim was to better understand and contextualize the results of
meta-analyses evaluating DMT, identify differences in methodology that might explain
their differing conclusions, and highlight areas for future research that will improve our
ability to develop clinical recommendations.
Methods: We conducted an overview of systematic reviews with meta-analyses
assessing the efficacy of DMT on disability progression in people with MS in PubMed
(Medline) and the Cochrane Database of Systematic Reviews.
Results: We included 22 meta-analyses in this overview: eight general (on >3 DMT),
11 specific (on ≤3 DMT), 2 that evaluated subsets, and 1 that evaluated long-term
effects. We found that there is good evidence that DMT improve short-term (≤2–3 years)
disability progression outcomes relative to placebo in people with relapsing-remitting
MS. However, results varied substantially between meta-analyses, and there is little
evidence of their efficacy in other populations or over longer periods. The relative effects of
individual DMT also remain unclear. The variance in results between meta-analyses may
be related to the substantial differences in inclusion criteria, which was reflected in the
limited overlap in included studies, as well as the year of meta-analysis publication. Of the
123 total unique studies included in the general meta-analyses, 77 (62.6%) were included
in only one meta-analysis. This incongruence was also evident in the included DMT. Six
of the 16 (37.5%) DMT evaluated in the general meta-analyses were only included in one
meta-analysis.
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Conclusions: Translating DMT efficacy studies into evidence-based clinical practice
requires greater methodological consistency in meta-analyses, more data on the relative
effects of DMT through head-to-head clinical trials, and better reporting of adverse
events.
Keywords: multiple sclerosis, disease modifying therapies, meta-analysis, systematic review, disability
progression
INTRODUCTION
Disease modifying therapies (DMT) that modulate, modify,
or suppress the immune system are a medication class
used to treat people living with multiple sclerosis (MS) (see
Supplementary Table 1 for a list of FDA-approved DMT).
As with other pharmacological treatments, systematic reviews
and meta-analyses of DMT efficacy are essential for the
development of effective, evidence-based clinical guidelines
(1). However, meta-analyses on this subject often do not
reach the same conclusions, which impedes translation of
findings into clinical practice. In this study, we compared
meta-analyses of DMT efficacy on MS disability progression
to assess differences in their results and methodologies,
and identify knowledge gaps in areas that are critical for
accurate risk-benefit assessment and the development of effective
guidelines.
MS is a complex disease of the central nervous system that
results in demyelination, axonal loss and neurodegeneration,
and often leads to significant accumulated disability over its
typical 30–40 year course. There is significant variation in MS
disease presentation and disease course after onset. At onset,
there are two main disease phenotypes: relapsing-remitting
(intermittent periods of markedly increased disability, followed
by significant or complete remission), and primary progressive
(continuous increase in disability with no remission). These
phenotypes are not evenly distributed through the population:
about 80–85% of people with MS initially experience relapsing-
remitting MS (RRMS) and the remaining 15–20% experience
primary progressive MS (PPMS) (2). MS disease course is
understood to have two aspects. The first is disease activity,
which is active disease pathology that may or may not
result in worsening disability and is assessed with relapse
rate and MRI imaging. The second is disease progression,
the worsening of disability separate from markers of disease
activity and is assessed with objective measures of worsening,
such as change in Kurtzke Expanded Disability Status Scale
(EDSS) (3).
The pathology of MS is currently understood to be immune-
mediated, incorporating several immune and neurodegenerative
processes, including either primary, or secondary (due to
inflammation) neurodegeneration. Consequently, DMT are a
major treatment option for people with MS. However, DMT
have a series of limitations. They are generally only effective for
RRMS, leaving those with progressive MS with limited treatment
options (4, 5). DMT are expensive and their cost continues to rise
rapidly. First-generation DMT (interferon β-1b, interferon β-1a
IM, and glatiramer acetate) were introduced with annual costs of
US$8,292- US$11,532 and their costs have risen 21–36% per year
(6). DMT can also have significant adverse side effects, including
risk of serious infections (7), and the long-term and relative
benefits remain unclear. These issues are particularly problematic
when you consider that patients often need long-term
treatment.
Because of their importance to the MS community, it
is essential that the effect of DMT on health outcomes is
well understood, including accurate risk-benefit assessment,
to provide a foundation for evidence-based clinical practice.
While there are several promising potential biomarkers, such
as neurofilaments and MRI metrics, to date, no effective
biomarker has been identified for the accurate assessment
of MS disease progression. In the absence of an effective
biomarker, surrogate measures, such as time to conversion to
secondary progressive MS (SPMS) or MRI metrics are used
to quantify MS disease progression. In this overview, we are
interested in the most inclusive measure of disability progression,
which encompasses the experience of both RRMS and PPMS
cases. Therefore, for the purposes of this review, disability
progression refers to measures of accumulated disability,
which is a major concern for people with MS, as the level
of accrued disability is directly correlated with quality of
life (8).
Several meta-analyses have evaluated the impact of DMT
on MS disability progression. However, their conclusions
vary substantially, making it challenging to synthesize them
into concrete clinical recommendations. This suggests that an
overview of reviews, or a systematic review of reviews, is
necessary to compare the results. Here we present an overview
of meta-analyses that evaluate the effect of DMT on disability
progression (measured as accumulated disability) in people with
MS, to better understand and contextualize the results, identify
differences in methodology that might explain differences in
results, and highlight areas for future research.
METHODS
Criteria for Considering Meta-Analyses for
Inclusion
The objective of the overview was to summarize the evidence of
DMT efficacy on disability progression in people living with
MS in published meta-analyses and to evaluate meta-analysis
methodology. Inclusion criteria are presented in Table 1.
Exclusion criteria were: (1) study does not include a meta-
analysis; (2) outcome measure not related to accumulated
disability.
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TABLE 1 | Overview inclusion criteria.
Category Inclusion criteria
Population People living with MS (any phenotype, pediatric or adult)
Intervention One or more DMT
Comparator Placebo or another DMT or dosage
Outcome Measure(s) of accumulated disability (e.g., sustained
disability progression)
Study design Meta-analysis
Search Methods for Identification of
Meta-Analyses
We conducted a search in PubMed (Medline) in June 2017 and
in the Cochrane Database of Systematic Reviews in November
2018. The searches for relevant articles employed search terms
for DMT and multiple sclerosis. (For the search terms, please see
Appendix 1 in the online supporting information). We classified
any immunomodulating or immunosuppressing treatment for
MS to be a DMT.
Data Collection and Analysis
Data Extraction and Management
One author (SC) extracted information on the citation details,
objective, study design, participant details, search details,
inclusion criteria, interventions, and outcomes, including quality
assessment instrument, from the included meta-analyses using
a standard form. The inclusion criteria we extracted from
each meta-analysis included study, participant, and intervention
criteria. Study criteria included publication date (if there was a
date range set on the search), study type (design and approach),
outcomes, language restriction, bias assessment criteria, and
sample size. Participant criteria included diagnosis criteria, age,
and phenotype. Intervention criteria included comparison group,
dosage and DMT. For meta-analyses that assessed multiple time
points, we included the longest follow-up that maintained most
of the included studies. We compared similar outcomes from
included meta-analyses (we did not gather results from the
individual studies included in the meta-analyses), separating
outcomes into risk, odds, and hazard ratios. Risk ratios, odds
ratios, and hazard ratios are all measures of probability, but
they differ considerably in their calculation and are not directly
comparable. The risk ratio is calculated as the probability of
an event occurring in one group divided by the probability of
it occurring in another group. The odds ratio is calculated as
the probability of an event occurring in a group divided by
the probability of the event not occurring. The hazard ratio
is calculated as the ratio of two hazard functions, the hazard
function for one group divided by the hazard function for
another (9). We did not have access to the data required to
convert one metric to another, and so presented and assessed
them separately. We prioritized results comparing an active
agent to placebo and collected this data if it was available. We
also collected data comparing active agents if the data were
adequately summarized. We did not collect information on dose
comparisons. We collected data from network meta-analyses
and traditional pairwise meta-analyses.We were particularly
interested in comparing meta-analyses with similar aims, and
so focused our attention on the general meta-analyses rather
than the specific meta-analyses. We defined general meta-analyses
as those that aimed to include all approved DMT or all DMT
returned by their search terms and specific meta-analyses as those
that aimed to include three or less DMT. From the general meta-
analyses, we extracted a list of the included studies and risk of bias
assessment results.
Data Synthesis
We compared the number of randomized controlled trials
(RCT) included in the general meta-analyses with the number
of available RCT. We calculated the number of available RCT as
the number of RCT included in general meta-analyses that were
published by the year before the search date, or the year before the
publication year of the meta-analysis, if no search date was stated.
If the publication year of a RCT was unknown, it was assumed
to be the year following the year of study completion. A RCT
was also considered available if it was included in a meta-analysis
published prior to the one being assessed. We could not access a
list of the studies included in one meta-analysis (10) and another
provided a truncated list (11), leaving the identity of some RCT
uncertain. Where RCT were not explicitly listed, we assumed
that they were already represented in the list of included RCT,
making our estimates conservative (i.e., meaning higher than the
actual percentage of available studies included). Observational
and review studies were excluded from this analysis, as they were
only included in one general meta-analysis (12).
We compared risk of bias assessment among the four general
meta-analyses that used the Cochrane Collective risk of bias
assessment tool.
Assessment of Methodological Quality of Included
Meta-Analyses
We assessed the methodological quality of the included meta-
analyses using the enhanced Overview Quality Assessment
Questionnaire (OQAQ) (13) (Supplementary Table 2). We
selected this tool because it has strong face and construct validity
(14). This tool includes ten items, nine that query the reporting
methodology of the study, which are scored by selecting yes, no,
partial or can’t tell and one overall assessment question (item
10), which asks assessors to rate the overall quality on a scale
from 1 to 7. We used the enhanced version, which incorporates
guidelines for its use (15).We assessed the reporting quality of the
included meta-analyses using the Quality of Reporting of Meta-
analyses (QUOROM) checklist (Supplementary Table 3). This
tool consists of 18 items, focusing on reporting in the abstract
and methods sections. One author (SC) evaluated the included
meta-analyses.
The same author (SC) assessed the quality of evidence using
GRADE (16). The GRADE approach results in four quality
of evidence ratings: high, moderate, low and very low. Meta-
analyses of RCT were initially graded as high quality evidence
and meta-analyses that included non-randomized studies were
initially graded as low quality evidence. All meta-analyses were
then evaluated for eight factors that might lower or raise the
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quality of evidence assessment: limitations in study execution,
inconsistency of results, indirectness of evidence, imprecision,
publication bias, magnitude of effect, confounding, and a dose-
response gradient.
RESULTS
Search Results
Our initial search returned 267 articles, including 24 meta-
analyses (Figure 1). We excluded two of these meta-analyses, as
they did not cover the subject area of this review. One evaluated
short-term suboptimal response criteria to first-line DMT (17),
and the second evaluated the effect of DMT on brain atrophy, a
potential but unvalidated marker of MS disease progression (18).
Our subsequent search returned 347 Cochrane reviews, none of
which met our inclusion criteria and were unique from our initial
search.
Description of Included Meta-Analyses
Twenty-two meta-analyses were included in this overview. The
characteristics of the includedmeta-analyses, including reporting
quality and quality of evidence scores, are presented in Tables 2,
3. All but two (28, 35) conducted systematic reviews of the
literature. Of these, 13 (65%) were systemic reviews of RCT,
five (25%) were systematic reviews of RCT and observational
studies and one (5%) was a systematic review of observational
studies and RCT extension trials (Table 2). Eight (40%) of the
included studies were network meta-analyses. Network meta-
analyses analyse both direct comparisons within trials and
indirect comparisons between trials (38). Two (10%) included a
number needed to treat analysis (Table 2). Seven (31.8%) meta-
analyses analyzed disability progression outcomes at more than
one time point (Table 3) and 3 (15.8%) analyzed outcomes of
assessed at different time points together. The most commonly
assessed time points were 3 months (8 studies; 36.4%) and 24
months (8 studies; 36.4%). Four meta-analyses (18.2%) did not
report or define the duration of their outcome or defined it
in such a way that it varied depending on the duration of the
included study (Table 3).
All included meta-analyses sought to evaluate the efficacy of
one or more DMT on health outcomes in people living with MS.
Sixteen (72.7) evaluated the effects in people with relapsing forms
of MS and four (18.2%) included people with all phenotypes of
MS. Two meta-analyses (9.1%) did not explicitly report the MS
phenotypes included in their study, although it can be inferred
that they included people living with relapsing MS (Table 2).
We discuss three of the included meta-analyses separately, as
they evaluated particular patient subgroups rather than a general
population or evaluated long-term effects. One evaluated the
effect of DMT on highly active RRMS and rapidly evolving severe
MS (24), the second evaluated the effect of DMT on patients
with larger treatment benefits (31) and the third evaluated the
long-term effects of interferon beta and glatiramer acetate (32).
Of the 19 remaining meta-analyses, eight (42.1%) were general
meta-analyses (10–12, 19–22, 29, 35), meaning that they aimed
to include all approved DMT or all DMT returned by their
search terms. The other 11 (67.9%) meta-analyses were specific
FIGURE 1 | Inclusion flowchart.
(20, 23, 25–28, 30, 33, 34, 36, 37), meaning that they focused on
three or less pre-specified DMT (Table 2). Eight reported results
as risk ratios (42.1%) relative to placebo, and six (31.6%) reported
results as odds ratios relative to placebo. Three studies (15.8%)
reported results as hazard ratios, two (10.5%) studies study did
not summarize the results in a risk, odds or hazard ratio, one
(5.3%) reported them only as number needed to treat (23), and
two studies did not report the results in comparison to placebo
(11, 30) (Table 3).
One general meta-analysis was not included in our assessment
of studies included in general meta-analyses because we could
not access a list of its included studies (10). However, it was
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included in all other analyses. Another meta-analysis (11) was
included in this assessment, although its list of included studies
was truncated; only providing information on 36 of 44 studies.
On review of the meta-data in forest plots, two studies displayed
data showing treatment effects that were counter to expectation
(10, 29). On review of the raw data it was clear that the
results had been inadvertently inverted. These were corrected
by taking the inverse of the reported odds or risk ratios. The
confidence intervals in these papers were asymmetrical even
when plotted on a logarithmic scale, which is atypical. We
did not see any clear cause for this asymmetry in the study
methods.
Assessment of the Methodological Quality
of Included Meta-Analyses
Quality of Reporting in Included Meta-Analyses
Themean percentage of OQAQ items designated “yes” was 85.4%
and the mean score for item 10 (rating ± SD) was 5.1 ± 1.7
(Table 3; Supplementary Table 2). Item 3, which queries the
reporting of inclusion criteria, had the lowest compliance, with 15
studies (68.2%) fulfilling it (Supplementary Table 2). The mean
percentage of QUOROM items designated “yes” was 76.3%. Item
14, which queries the reporting of quantitative data synthesis, had
the lowest compliance, with 8 meta-analyses (36.4%) fulfilling it
(Supplementary Table 3).
Quality of Evidence in Included Meta-Analyses
The quality of evidence in the included meta-analyses ranged
from very low to moderate on the GRADE scale (Table 3). Of
the 23 meta-analyses/outcome combinations, 5 (21.7%) were
graded moderate, 9 (39.1%) were graded low and 9 (39.1%) were
graded very low-quality evidence (Supplementary Table 4). The
most common cause for a downgrade in evidence quality was
imprecision, with the majority of meta-analyses unable to rule
out no effect (Supplementary Table 4).
Effect of Interventions
Subgroups and Long-Term Effects
There was little data on the long-term (>2–3 years) effects
of DMT on MS health outcomes in the meta-analyses
included in this overview. In two of the largest meta-
analyses we reviewed, most studies were <3 years duration.
In one meta-analysis, the average duration was only 1.75
years or 21 months (22). Only one meta-analysis returned
by our search (32), assessed long-term effects and only did
so for two DMT, glatiramer acetate and interferon beta.
This analysis of 14 studies found that glatiramer acetate and
interferon beta significantly reduced the time to progression
to EDSS 6.0 (pooled HR: 0.49; 95%CI: 0.34–0.69; p < 0.001;
Supplementary Table 8) (32).
Subgroup analyses were also rare, with only two meta-
analyses focusing on them. The first found that in the small
number of RRMS studies (n = 6) where there was a subgroup
analysis, treatment effects on disability progression were greater
in younger participants (younger relative effect (RE): 0.82 vs.
older RE: 1.28; p: 0.017; Supplementary Table 8) (31). The
second evaluated two studies that included a subgroup analysis
of highly active RRMS or rapidly evolving severe MS (24). A
numerical, but not statistically significant, increase in three-
month confirmed disability progression in patients treated with
fingolimod compared to those treated with natalizumab was
found (Supplementary Table 8).
One meta-analysis included a subgroup analysis as a
secondary analysis (35), comparing first and second line DMT
and injectable and oral DMT. The authors found no significant
difference between these groups (first line RR: 0.72 vs. second line
RR: 0.72, p= 0.96; injectable RR: 0.75 vs. oral RR: 0.74, p= 0.92;
Supplementary Table 8).
DMT vs. Placebo
Overall, the evidence suggests that, when compared to placebo,
disease modifying therapies reduce the risk of disability
progression in people with RRMS (19, 22, 25, 27, 34–37)
(Figures 2, 3; Supplementary Tables 5, 6, 7). Twenty-one (84%)
of the 25 DMT/dosage combinations assessed with RR in
the included meta-analyses had RR <1, indicating that the
treatment had a beneficial effect compared to placebo (Figure 3;
Supplementary Table 6). Nine (36%) had upper 95% confidence
intervals <1. Among the 32 DMT/dosage combinations assessed
with OR in the included meta-analyses, 21 (65.6%) had OR
<1 and 4 (12.5%) had upper 95% confidence intervals <1
(Figure 2; Supplementary Table 5). When analyzed as a group,
DMT significantly reduced the risk of disability progression
compared to placebo (RR: 0.72; 95%CI: 0.66–0.79; p< 0.001; dark
green data in Figure 3) (35). Some of the observed reductions
in disability progression were substantial, with the reduction in
the risk of disability progression confirmed after 3 and 6 months
ranging from 19 to 68% for various DMT (22).
However, not all DMT or all dosages of the same DMT
significantly affected disability progression (Figures 2, 3). For
example, in a systematic review and meta-analysis, of eight
DMT (interferon beta-1b (Betaseron/Betaferon), interferon
beta-1a (Avonex), interferon beta-1a (Rebif), glartiramer acetate,
natalizumab, azathioprine, mitoxantrone and intravenous
immunoglobulins) only two, natalizumab (OR: 0.56; 95%CI:
0.42–0.74), and interferon beta-1a (Rebif) (OR: 0.65; 95%CI:
0.45–0.93) reduced the odds of disability progression over 24
months (21). Similarly, the Canadian Agency for Drugs and
Technologies in Health (CADTH) found that while all ten
treatments (varying DMT and dosages) directly compared
to placebo in their analysis numerically reduced the risk of
sustained disability progression, only six (interferon beta-1a (44
mcg and 30 mcg), natalizumab, fingolimod, teriflunomide 14mg
and dimethyl fumarate) had a significant effect (19).
There was also substantial variability in outcomes for the
same DMT. Figures 2, 3 demonstrate that there was variance
in the relative risk or the odds of progression for natalizumab
and interferon beta-1a compared to placebo, with confidence
intervals that do not overlap. However, it should be noted that
while the meta-analyses of interferon beta-1a included different
studies (one only included PRISMS, the other included other
studies as well), in the cases where the analyzed studies were
identified, the data on natalizumab came from the same study
(AFFIRM) in all meta-analyses.
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DMT vs. DMT
Based on their inclusion criteria, 13 (59.1%) of the meta-analyses
included in this overview sought to compare effect of different
DMT. However, limited direct comparisons were possible. In
their network meta-analysis of 48 studies, Hadjigeorgiou et al.
(10) could only make six direct pairwise comparisons between
treatments. Two were statistically significant: Interferon beta-
1a (Avonex) was worse than interferon beta-1b (Betaferon) [OR
= 0.36 (0.17,0.75)] and Betaferon was worse than glatiramer
acetate [OR = 0.69 (0.59, 0.91)]. Several studies found little
or no difference between DMT or different dosages of the
same DMT over time periods of up to 5 years [e.g., 28,30]
(Supplementary Tables 5–8).
Several network meta-analyses evaluated the relative effects
of DMTs on disability progression. These analyses yielded
incongruent results. For example, the two network analyses that
presented surface under the cumulative ranking curve (SUCRA)
scores (21, 22) did not agree. Mitoxantrone is ranked first in the
Filippini et al. (21) network analysis but is not included in the
Fogarty et al. (22) analysis. Interferon beta-1b was ranked sixth
out of eight DMT in the Filippini et al. (21) analysis but was
ranked first out of nine DMT in the Fogarty et al. (22) analysis.
There was also disagreement within network meta-analyses.
Fogarty et al. (22) found that although interferon-beta-1b 250
mcg was the least effective after 3 months (SUCRA score: 30%), it
was the most effective of the eight DMT evaluated after 6 months
(SUCRA score: 92%).
Comparison of General Meta-Analysis
Methodology
Inclusion Criteria for General Meta-Analysis
The general meta-analyses included in this overview had
different study, participant and intervention inclusion criteria
(Table 2). The study inclusion criteria for study design ranged
from permitting observational studies to limiting included
studies to phase III RCT. The participant MS phenotype
inclusion criteria was also variable. Four general meta-analyses
(50%) only included studies of RRMS and two meta-analyses
(25%) included studies of any type of relapsing MS (RRMS,
SPMS with relapses, or progressive-relapsing MS, PRMS). The
remaining two meta-analyses (25%) included studies of all types
of MS.
All included general meta-analyses had pre-specified outcomes
of interest. These included a range of outcome metrics (Table 2),
some of which were not well defined. In the general meta-analyses
included in this overview, 75% assessed a general disability
progression metric. This included confirmed, unconfirmed,
sustained, unsustained, undefined, and the rate of disability
progression. Except for the rate of disability progression, these
outcomes were not clearly defined, meaning they did not give
particular EDSS or other disability assessment thresholds.
A total of 16 DMTs were evaluated for their effect on MS
disease progression in the eight general meta-analyses included in
this overview. Inclusion for a particular DMT ranged from one to
eight studies. The most common were INFB-1a and natalizumab,
which were included in all of the general meta-analyses. Six of the
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FIGURE 2 | The odds of disease progression (measured as accumulated disability) presented here for comparison (odds ratio ± 95%CI after treatment with various
DMT compared to placebo, values <1 indicate an effect). For each DMT, each line shows the results of a different meta-analysis/dosage combination.
Source citation and dosages (if specified) are given in the data label. These could not be consolidated due to overlap in included studies between meta-analyses).
* Indicates that the analysis was a traditional meta-analysis, all others were network met-analyses. + Indicates analyses that included all MS phenotypes, all others
included only relapsing phenotypes.
evaluated DMT (37.5%) were only assessed in one general meta-
analysis. This may reflect that more contemporary meta-analyses
often focused on those DMTs that have been approved for clinical
use and considered effective in improving MS outcomes. On
average, a DMT was assessed in less than half of the general
meta-analyses (3.75; 46.9%).
Studies Included in General Meta-Analyses
There was limited congruence in included studies between
general meta-analyses. The general meta-analyses in this overview
all included<60% of the available RCT (Table 3). On average, the
general meta-analyses included 39% of the available RCT. Among
the seven general meta-analyses for which the included studies
were known, the median number of studies included by any one
meta-analysis was 29 and ranged from 13 to 66. Of the 123 total
unique studies (93 RCT) included in these seven meta-analyses,
77 (62.6%) were included in only one meta-analysis (Figure 4).
The average was inclusion in 1.9 meta-analyses. The nine
most commonly included studies were the European/Canadian
GA trial (39), EVIDENCE (40), and FREEDOMS I (41) (5
inclusions); IFNB-MS (42) and BEYOND (43) (6 inclusions); and
AFFIRM (44), Copolymer I (45), MSCRG (46), and PRISMS (47)
(7 inclusions).
There was variance in the risk of bias assessments, even
when the same risk of bias assessment tool was used. Four of
the general meta-analyses included in this overview used the
Cochrane Collective risk of bias assessment tool, which includes
seven assessment criteria. The authors using this tool determined
if each study included in their analysis had a low, high or unclear
risk of bias for each criterion. The nine studies most commonly
included in the general meta-analyses had between one and seven
criteria rated “low risk” by the four author groups. The minimum
range in the number of assessment criteria ranked “low risk” by
the four author groups for a given study was three criteria (three
studies) and the maximum range was five criteria (three studies)
(Table 4).
DISCUSSION
The majority of included meta-analyses evaluated the impact
of one or more DMT on disability progression in people with
Frontiers in Neurology | www.frontiersin.org 19 January 2019 | Volume 9 | Article 1150
Claflin et al. Systematic Overview MS-Related DMT Effects
FIGURE 3 | Relative risk of disease progression presented here for comparison (RR ± 95% CI after treatment with various DMT compared to placebo, values <1
indicate an effect). For each DMT, each line shows the results of a different meta-analysis/dosage combination. Source citation and dosages (if specified)
are listed in the data label. These could not be consolidated due to overlap in included studies between meta-analyses. All meta-analyses included studies of people
with relapsing MS. Combined indicates an aggregation of DMT, including dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b,
natalizumab, peg-interferon beta-1a, and teriflunomide. * Indicates that the analysis was a traditional meta-analysis, all others were network met-analyses.
relapsing MS. However, they used a range of methodological
approaches, with different search strategies, inclusion criteria and
assessment criteria. The included meta-analyses also varied in
age by 17 years, from 1999 to 2016. The general meta-analyses
included in this overview had limited overlap in included studies
and, on average, included less than half of the available RCT.
Overall, the meta-analyses included in this overview offer
good evidence that, in general, DMT improve short-term (≤2–
3 years) disability progression outcomes in adults with relapsing
forms of MS compared to placebo. However, the evidence varies
between meta-analyses and there is little evidence of their effect
on people with other MS phenotypes, on juveniles with MS or
of long-term (>3 years) effects. It also remains unclear which
DMT have the greatest efficacy and under what circumstances
they perform best. To further our understanding of MS disease
progression, meta-analytical methodological consistency must
be improved. In order to translate findings in this area into
evidence-based clinical practice, we need a greater understanding
of the relative effects of DMT on health outcomes, the effects
of DMT on patient subgroups, the long-term effects of DMT
and DMT adverse effects. Future research should address these
knowledge gaps.
Methodological Inconsistency
There was substantial methodological inconsistency in the
general meta-analyses included in this overview, with different
study, participant and intervention inclusion criteria. Some
of this variance is inevitable. For example, the publication
dates of included studies necessarily varied in accordance with
the meta-analysis publication date. Some of the variance may
reflect logistical challenges. For example, three meta-analyses
restricted their search to literature published in English—this
may result from limited translation resources. However, many
of the differences in inclusion criteria are matters of author
discretion. For example, although all meta-analyses included
randomized controlled trials (RCT), one author group restricted
included studies to phase III RCT (10), while another broadened
their criteria to include certain observational studies (12) and
another excluded retrospective or ad hoc RCT analyses (10).
As demonstrated by the relatively small amount of overlap
Frontiers in Neurology | www.frontiersin.org 20 January 2019 | Volume 9 | Article 1150
Claflin et al. Systematic Overview MS-Related DMT Effects
in included studies and DMT, these differences in inclusion
criteria change which studies and which DMT are included in an
analysis. Inclusion criteria also determine the generalizability of
the results.
The meta-analyses also had different outcomes of interest and
different follow-up durations for those outcomes. Some included
more than one, introducing potentially significant sources of
inconsistency into their analyses. This reflects the limitations of
studies in this area. At least two of the meta-analyses included in
this overview mixed outcomes measured at different time points
(e.g., 3- and 6-month sustained disability progression) in their
analyses. Because duration significantly affects the number of
participants who progress, these outcomes are not comparable
and should not be assessed simultaneously. The definition of
disability progression also varied between meta-analyses and,
at times, between studies included in the meta-analyses. The
diversity and ambiguity of outcomes also affects comparisons
between meta-analyses. The variability in outcome measures
reduces replication of data and makes it difficult to directly
compare results (25).
There was also substantial variability in the results of the
Cochrane Collective risk of bias assessment tool. The tool
has seven criteria and was employed by four general meta-
analyses in their evaluations of risk of bias. Among the
author groups that used it, the evaluations of the nine most
commonly included studies had ranges of up to five criteria.
Risk of bias tools are inherently subjective, making consistency
between different research groups difficult to achieve. However,
these differences do affect the interpretation of the results of
particular studies in these meta-analyses and may partially
explain the different conclusions reached by different author
groups.
Finally, baseline characteristics were not consistently included
in the meta-analyses in this overview. Weideman et al. (48)
demonstrated that DMT efficacy is age dependent. Their meta-
analysis suggests that approximately 67% of the variability in
DMT efficacy is explained by the subject’s age, making age an
essential covariate in analyses of DMT efficacy. Therefore, we
suggest that future meta-analyses follow the example of Fogarty
TABLE 4 | Results of the risk of bias assessment from four general meta-analyses
on the effect of DMT on MS disease progression, using the Cochrane Collective
risk of bias assessment tool.
Study Number of
observations
Median “low
risk” criteria
Range of
“low risk”
criteria
AFFIRM 4 6 4–7
BEYOND 3 4 4–6
COPOLYMER I 4 3 2–6
European/
Canadian GA
trial
2 4 2–6
EVIDENCE 2 4 3–5
FREEDOMS I 3 5 4–7
IFNB–MS 4 3 1–5
MSCRG 4 4 2–5
PRISMS 4 6 5–7
The tool has seven criteria. Each criterion assessed as “low risk” was counted, giving
a numerical value from 0 to 7. The number of observations indicates how many meta-
analyses assessed the study in question, and the median and range refer to the summary
statistics for the number of criteria assessed as :low risk.” For example, the AFFIRM
study was assessed by 4 general meta-analyses, and a median of 6 out of 7 risk of bias
assessment criteria were determined to be “low risk,” with a range of 4–7 criteria.
FIGURE 4 | This graph depicts the number of general meta-analyses in which a given study was included. There were 123 unique studies included in meta-analyses
evaluating the effect of DMT on disease progression that provided a list of included studies [Zintzaras et al. (10) was excluded]. For example, 77 of the included
studies were included by one of the seven general meta-analyses that provided a list of included studies.
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et al. (22) in including age and other baseline characteristics as
co-factors in meta-analytical models.
Greater adherence to a standard meta-analysis methodology
for the aggregated analysis of RCT and other study types, such as
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA), would improve our understanding of study
outcomes and enhance our ability to translate study findings into
clinical practice. However, we acknowledge that the variance in
methodology may derive from different interpretations of these
standards. Further, standardized search strategies may improve
overlap in included studies.
The Relative Effectiveness of DMT on
Disease Progression
A greater understanding of the relative effects of DMT, in
comparison to each other and on different subsets of the MS
population, is essential for the development of evidence-based
clinical practice. Unfortunately, there is little evidence on the
relative effects of DMT. There are few head-to-head studies of
DMT efficacy, forcing researchers to rely on indirect approaches,
which are less generalizable and have less analytical strength than
direct comparisons. The results that do exist are often difficult to
compare, as they are usually presented as lists of comparisons of
one DMT vs. another without a ranking or greater context for
the comparison, such as a surface under the cumulative ranking
curve (SUCRA) score (49). Instead, these comparisons have no
bearing on each other. For example, if A is found to be more
effective than B and if C is found to be more effective than A, that
does not mean that C is more effective than B. This likely results
from the inconsistency and paucity of the data comparing DMT,
as rankings such as SUCRA are only appropriate when there are
consistent preferences between interventions (49). However, this
presents a serious barrier to the translation of this work to clinical
practice.
Additionally, the available information is inconsistent. In part,
this may reflect methodological differences between network
meta-analysis studies and again, we support the conclusion
that greater adherence to conduct and reporting standards
(e.g., the 2015 PRISMA standards) is needed (50). The results
of the network meta-analyses included in this overview also
indicate that the timing of disability assessment may significantly
impact study outcomes and consequently meta-analyses efficacy
rankings. This should be taken into account in future analyses.
DMT Efficacy in Patient Subgroups and
Long-Term
There is also very little data on the effect of DMT on subsets
within the MS population or on long-term effects. Only two
of the meta-analyses returned in our search focused on MS
subpopulations, but the results are of great interest to the MS
community and warrant further research. This is a significant
knowledge gap, as subgroup analyses, such as those based
on age or disease severity, are essential for effective, targeted
treatment. The absence of data likely results from the logistical
and economic challenges inherent in running high quality
clinical trials, and the lack of interest in this area from funders.
Fortunately, emerging study methodologies should make a
substantial difference in this area. Large, international databases,
such as MSBase, offer observational datasets containing more
than 50,000 patients, which allow for the robust evaluation of MS
patient subsets (51).
Without data on long-term effects, it is impossible to assess
the true impact of DMT treatment in a disease that often
extends over more than 40 years. However, only one meta-
analyses included in this overview focused on long-term effects.
Again, this is likely a reflection of an absence of data due to
the ethical, logistical and economic difficulties of running long-
term intervention studies. Novel study designs may provide an
alternative means of assessing the long-term effects of DMT.
Long-term follow-up studies of DMT efficacy using untreated
natural history comparators [e.g., (52)] and natural experiments
comparing treated and untreated populations could shed light on
the long-term impacts of DMT.
Adverse Effects
Reporting of adverse events is sparse in studies of DMT efficacy.
Consequently, although nine of the meta-analyses included in
this overview (40.9%) sought to evaluate adverse events, few
could reach any meaningful conclusions. One study found that
only 20 of the 48 RCT they analyzed actively monitored adverse
events. More than half of the studies did not report serious
adverse events and only one gave sufficient information on how
a serious adverse event was defined (21). Similarly, in another
study, adverse events in 48 studies were reported but only two
comparisons could be made (11).
Information on adverse events is essential for the accurate
calculation of risk-benefit ratios and is critical for the
implementation of evidence-based clinical practice. A greater
understanding of adverse events requires better reporting of
such events. We would like to echo the conclusion of others
who call for mandatory long-term follow-ups to short-term (2–
3 year) RCTs on DMT efficacy and suggest that the reporting of
adverse events and serious adverse events also be a mandatory
component of RCT (21).
LIMITATIONS
This overview addressed its initial objective, which was to
evaluate both the current evidence of DMT efficacy on disability
progression in people withMS andmeta-analysis methodology to
identify knowledge gaps impeding the development of evidence-
based clinical recommendations. However, it has four main
limitations. First, the inability to combine the results of all
included meta-analyses into a single analysis. This is outside
the purview of this overview but is a worthy goal for a
future work. It will require gathering all included studies and
integrating them into a single meta-analysis. Second, study
evaluation and data extraction by a single author, which can
introduce bias. This was done due to logistical constraints.
Third, the methodological inconsistency of the included meta-
analyses, discussed above. Fourth, the inclusion of both direct
and indirect evidence. Several of the included meta-analyses
are network meta-analyses, which integrate direct and indirect
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evidence. While they present some advantages over traditional
meta-analysis and may even improve the quality of evidence
over traditional approaches, they also have methodological
and conceptual limitations, such as transitivity, the calculation
of indirect effects through a common comparator. Network
meta-analyses also rely on the same assumptions as traditional
meta-analysis, namely the homogeneity of aggregated data
(53, 54).
The third and fourth limitations lower the quality of evidence
included in this overview and further support our conclusion that
further research in this area is needed to develop evidence-based
clinical recommendations.
CONCLUSIONS
There is evidence that DMT improve disability progression
outcomes in people living with relapsing MS relative to
placebo, but further work is needed to develop robust,
comprehensive clinical recommendations. We support efforts
to improve adherence to conduct and reporting standards
(e.g., PRISMA) for meta-analyses, including network meta-
analyses. We suggest that, where possible, the assessment of
patient subgroups and long-term effects are prioritized, as
well as recently approved DMT and we advocate for the
development of adverse event and serious adverse event reporting
standards.
More information is needed on the extent of DMT treatment
benefits, in order to ascertain which subgroups respond best
to treatment and under what circumstances. Further, greater
information is needed on the relative, adverse, and long-term
effects of DMT for accurate risk-benefit assessment and the
development of evidence-based clinical practice.
Further, we initially set out to conduct an overview of all
aspects of MS disease progression but could not due to the
scarcity of related meta-analyses on neurodegeneration, genetics,
and modifiable risk factors and interventions [but see (55, 56)].
This study has illustrated the significant challenges of conducting
meta-analyses and systematic reviews in this area. We hope that
future research will address remaining knowledge gaps.
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